COVID-19 drug: Cipla to price generic version of remdesivir below Rs 5,000 per vial, to be available in 8-10 days

By: |
Published: June 23, 2020 9:02 PM

Hyderabad-based drug firm Hetero on Sunday said that it will price its generic version of the drug in the range of Rs 5,000-6,000 per dose.

Remdesivir, Coronavirus, COVID-19, Coronavirus drug, COVID-19 drug, Cipla, antiviral drug, Hetero, United States Food and Drug Administration, USFDA, Emergency Use Authorisation, EUA, Drug Controller General of India, DCGI, Jubilant Life Sciences, Gilead Sciences Inc On being asked about the launch of the drug, Cipla said: “We have started commercial manufacturing, and the product will be available in the next 8-10 days.”

Pharma major Cipla will price its generic version of antiviral drug remdesivir at less than Rs 5,000 per vial in keeping with its conviction of providing access to the medicines at affordable cost, the company said on Tuesday.

“In line with our overall philosophy of driving access and affordability, the drug will be priced at less than Rs 5,000 per vial vial for injection 100 mg — amongst the lowest pricing for remdesivir globally,” Cipla said in an e-mailed response to PTI.

On being asked about the launch of the drug, the company said: “We have started commercial manufacturing, and the product will be available in the next 8-10 days.”

Hyderabad-based drug firm Hetero on Sunday said that it will price its generic version of the drug in the range of Rs 5,000-6,000 per dose.

Remdesivir is the only United States Food and Drug Administration (USFDA)-approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalised with suspected or laboratory confirmed COVID-19 infection.

Cipla has been granted regulatory approval by the Drug Controller General of India (DCGI) for restricted emergency use in the country as part of the accelerated approval process considering the urgent and unmet medical need, the company said on Sunday.

In May, domestic pharma firms Hetero, Cipla and Jubilant Life Sciences entered into non-exclusive licensing agreements with drug major Gilead Sciences Inc for manufacturing and distribution of remdesivir.

According to the Union health ministry update, the total number of COVID-19 cases in the country stood at 4,40,215 on Tuesday and the death toll was at 14,011.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Health ministry says Covid-19 to increase healthcare spend by a fifth during FY22-FY26
2Ebola spreading in western Congo with nearly 50 confirmed cases: WHO
3COVID-19: Delhi records 1,246 new cases, lowest in last 35 days; LNJP to have capital’s second plasma bank